MediWound Ltd. (NASDAQ:MDWD – Get Free Report) Director David Morton Fox bought 3,537 shares of MediWound stock in a transaction dated Monday, June 1st. The stock was acquired at an average cost of $14.11 per share, for a total transaction of $49,907.07. Following the purchase, the director directly owned 22,283 shares in the company, valued at approximately $314,413.13. The trade was a 18.87% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
MediWound Trading Down 0.4%
Shares of NASDAQ MDWD opened at $13.76 on Wednesday. The firm has a market capitalization of $176.82 million, a PE ratio of -6.09 and a beta of 0.16. MediWound Ltd. has a 1 year low of $13.54 and a 1 year high of $22.48. The firm’s 50-day moving average is $16.56 and its 200-day moving average is $17.40.
MediWound (NASDAQ:MDWD – Get Free Report) last issued its earnings results on Wednesday, May 27th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.42. The company had revenue of $1.48 million for the quarter, compared to analyst estimates of $3.37 million. MediWound had a negative net margin of 180.30% and a negative return on equity of 67.22%. During the same quarter last year, the firm earned ($0.07) EPS. As a group, equities research analysts anticipate that MediWound Ltd. will post -2.49 earnings per share for the current fiscal year.
Institutional Investors Weigh In On MediWound
Wall Street Analyst Weigh In
A number of equities research analysts recently commented on MDWD shares. Wall Street Zen upgraded MediWound from a “strong sell” rating to a “sell” rating in a report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of MediWound in a report on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective on shares of MediWound in a report on Thursday, May 28th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $32.00 price objective (down from $33.00) on shares of MediWound in a report on Wednesday, May 27th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $34.00.
View Our Latest Report on MediWound
About MediWound
MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.
The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.
Featured Articles
- Five stocks we like better than MediWound
- Marvell Stock Soars on NVIDIA’s Trillion-Dollar Nod
- FirstCash Turns Pawn Into a Growth Machine
- HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead?
- Aggressive Insider Buying Signals Opportunity in 3 Risky Stocks
Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.
